Is Glaukos (GKOS) Undervalued Following Record Sales And Higher 2026 Guidance?
Glaukos (GKOS) is back in focus after reporting record second quarter net sales, supported by iDose TR and the Epioxa launch, and raising its full year 2026 net sales guidance.
See our latest analysis for Glaukos.
The earnings beat and higher 2026 sales guidance have fed into strong momentum for Glaukos, with a 30 day share price return of 17.69% and year to date share price return of 62.59%. Over a longer horizon, the 1 year total shareholder return of 112.66% suggests recent enthusiasm has added to already strong compounding.
If Glaukos has you looking closer at eye care and medical technology, it can also be useful to see what else is moving in related themes using the 43 healthcare AI stocks.
Glaukos now sits on a fast growing eye care platform and a stock that has already moved significantly. The key tension is simple: are you looking at a quality business that is also reasonably priced, or one investors already pay a premium for?
Most Popular Narrative: 9.1% Overvalued
Glaukos closed at $180.02 against a narrative fair value of $165. This gap reflects a story built on rapid product adoption and richer margins over time.
Glaukos' pipeline diversification into corneal health (Epioxa approval expected in late 2025/early 2026), novel glaucoma devices, and early-stage retinal programs positions the company to benefit from increased diagnostic rates and expanding access to ophthalmic interventions globally, providing avenues for future top-line growth and risk mitigation against single-product dependency.
Investors may be curious about what would need to occur for Glaukos to justify a richer valuation than many medical equipment peers. The narrative emphasizes faster revenue compounding, rising profitability, and a higher future earnings multiple that assumes the current product set is only the beginning.
Result: Fair Value of $165 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to watch for reimbursement changes around iDose and any slower than expected Epioxa launch, which could quickly challenge the bullish Glaukos narrative.
Find out about the key risks to this Glaukos narrative.
Another View: SWS DCF Flags Glaukos as Deeply Undervalued
The narrative fair value of $165 suggests Glaukos trades at a premium to that story. Yet the SWS DCF model points in the opposite direction, with Glaukos at $180.02 and an estimated future cash flow value of $380.09, or about 52.6% higher. Which signal do you trust more when expectations are already elevated?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Glaukos for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
After weighing these mixed signals on Glaukos, it makes sense to move quickly and review the details for yourself rather than rely on headlines alone. To see what is driving the optimistic view on the company, start with the 2 key rewards.
Looking for more investment ideas beyond Glaukos?
If Glaukos has sharpened your focus on opportunities, do not stop here. Broaden your watchlist using targeted stock ideas surfaced by the Simply Wall St Screener.
- Spot potential bargains early and review companies that appear mispriced on quality and value using the 51 high quality undervalued stocks.
- Prioritise resilience and check out businesses that score well on balance sheet strength through the solid balance sheet and fundamentals stocks screener (49 results).
- Hunt for underfollowed opportunities by scanning the screener containing 19 high quality undiscovered gems that still show solid underlying fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com